Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): A randomised controlled trial

BMC Nephrology

Volumn 9, Issue 1, 2008, Pages

  Fassett, Robert G ^a,b,d   Healy, Helen ^a   Driver, Ritza ^b   Robertson, Iain K ^c   Geraghty, Dominic P ^c   Sharman, James E ^d   Coombes, Jeff S ^b,d  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b LAUNCESTON GENERAL HOSPITAL   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASTAXANTHIN; AZATHIOPRINE; BIOASTIN; CYCLOSPORIN; ISOPROSTANE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTRAXIN 3; PLACEBO; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; SERUM AMYLOID P; XANTHOPHYLL;

ADULT; ANTIOXIDANT ACTIVITY; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; AUGMENTATION INDEX; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FATTY ACID BLOOD LEVEL; HEART AFTERLOAD; HEART LEFT VENTRICLE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ARTERITIS; ARTERY; BLOOD; DRUG EFFECT; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PULSATILE FLOW;

ARTERIES; ARTERITIS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; HUMANS; KIDNEY TRANSPLANTATION; OXIDATIVE STRESS; POSTOPERATIVE PERIOD; PULSATILE FLOW; RESEARCH DESIGN; SERUM AMYLOID P-COMPONENT; XANTHOPHYLLS;

EID: 64249172293     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-9-17     Document Type: Article

References (49)

1. Cardiovascular morbidity and risk factors in renal transplant patients. S Aakhus K Dahl TE Wideroe, Nephrol Dial Transplant 1999 14 3 648 654 10.1093/ndt/14.3.648 10193814
2. Impact of aortic stiffness on survival in end-stage renal disease. J Blacher AP Guerin B Pannier SJ Marchais ME Safar GM London, Circulation 1999 99 18 2434 2439 10318666
3. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. W Sutherland R Walker M Ball S Stapley M Robertson, Transplant Proc 1995 48 227 236
4. Oxidative stress and antioxidant capacity in urine of renal transplant recipients predict early graft function. D Shoskes A Shahed S Kim, Transplant Proc 2001 33 984 10.1016/S0041-1345(00)02297-1 11267157
5. Serum paraoxonase activity changes in uremic and kidnet transplant patients. G Paragh L Asztalos I Seres, Nephron 1999 83 126 131 10.1159/000045489 10516491
6. Increased low density lipoprotein oxidation in stable kidney transplant recipients. H Ghanem M van den Dorpel W Weimar, Kidney Int 1996 49 488 493 10.1038/ki.1996.69 8821834
7. Oxidation of low-density lipoproteins in renal transplant recipients. F Cofan D Zambon C Rodriguez, Transplant Proc 1999 31 6 2333 2334 10.1016/S0041-1345(99)00365-6 10500604
8. Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. ZA Massy C Maziere S Kamel M Brazier G Choukroun C Tribouilloy M Slama M Andrejak JC Maziere, Pediatr Nephrol 2005 20 3 380 382 10.1007/s00467-004-1623-9 15549414
9. Cyclosporine induced oxidative stress and altered antioxidant defences in plasma and erythrocytes. LA Fletcher RG Fassett RS Richards JS Coombes, Redox Report 2005 10 1 2 8 10.1179/135100005X21543 15829105
10. Cyclosporine A-induced changes to erythrocyte redox balance is time course-dependent. LA Lexis RS Richards RG Fassett JS Coombes, Basic Clin Pharmacol Toxicol 2005 97 3 135 140 10.1111/j.1742-7843.2005.pto-973120.x 16128906
11. Antioxidant supplementation enhances erythrocyte antioxidant status and attenuates cyclosporine-induced vascular dysfunction. LA Lexis A Fenning L Brown RG Fassett JS Coombes, Am J Transplant 2006 6 1 41 49 10.1111/j.1600-6143.2005. 01154.x 16433755
12. The role of antioxidants in preventive cardiology. E Rimm MJ Stampfer, Curr Opin Cardiol 1997 12 2 188 194 10.1097/00001573-199703000-00016 9192489
13. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. K Gey P Puska P Jordan U Moser, Am J Clin Nutr 1991 53 1 326S 334S 1985406
14. Vitamin E consumption and coronary artery disease in men. EB Rimm MJ Stampfer A Ascherio E Giovannucci G Colditz W Willett, N Engl J med 1993 328 20 1450 1456 10.1056/NEJM199305203282004 8479464
15. Vitamin E consumption and the risk of coronary heart disease in women. MJ Stampfer C Hennekens J Manson C GA B Rosner W Willett, N Engl J Med 1993 328 20 1444 1449 10.1056/NEJM199305203282003 8479463
16. Vitamin E consumption and coronary artery disease in men. E Rimm MJ Stampfer A Ascherio E Giovannucci G Colditz W Willett, N Engl J med 1993 328 20 1450 1456 10.1056/NEJM199305203282004 8479464
17. Oxidative stress, nutrition and health. Experimental strategies for optimisation of nutritional antioxidant intake in humans. B Halliwell, Free Radic Res 1996 25 1 57 74 10.3109/10715769609145656 8814444
18. In vivo antiperoxidative effect of 9-cis beta-carotene compared with that of the all trans isomer. G Levin M Yeshurun S Mokady, Nutr Cancer 1997 27 3 293 297 9101560
19. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 9326 23 33 10.1016/S0140-6736(02)09328-5 12114037
20. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. S Yusuf G Dagenais J Pogue J Bosch P Sleight, N Engl J Med 2000 342 3 154 160 10.1056/NEJM200001203420302 10639540
21. Haematococcus astaxanthin: applications for human health and nutrition. M Guerin ME Huntley M Olaizola, Trends Biotechnol 2003 21 5 210 216 10.1016/S0167-7799(03)00078-7 12727382
22. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. FJ Pashkow DG Watumull CL Campbell, Am J Cardiol 2008 101 10A 58D 68D 10.1016/j.amjcard.2008.02.010 18474276
23. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. SJ Lee SK Bai KS Lee S Namkoong HJ Na KS Ha JA Han SV Yim K Chang YG Kwon, Mol Cells 2003 16 1 97 105 14503852
24. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. K Ohgami K Shiratori S Kotake T Nishida N Mizuki K Yazawa S Ohno, Invest Ophthalmol Vis Sci 2003 44 6 2694 2701 10.1167/iovs.02-0822 12766075
25. Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). GJ Gross SF Lockwood, Life Sci 2004 75 2 215 224 10.1016/j.lfs.2003.12.006 15120573
26. Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats. GJ Gross SL Hazen SF Lockwood, Mol Cell Biochem 2006 283 12 23 30 10.1007/s11010-006-2217-6 16444582
27. Inhibition of low-density lipoprotein oxidation by astaxanthin. T Iwamoto K Hosoda R Hirano H Kurata A Matsumoto W Miki M Kamiyama H Itakura S Yamamoto K Kondo, J Atheroscler Thromb 2000 7 4 216 222 11521685
28. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. RP Mason MF Walter HP McNulty SF Lockwood J Byun CA Day RF Jacob, J Cardiovasc Pharmacol 2006 47 Suppl 1 S7 14 10.1097/00005344-200605001-00003 16785833
29. Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation. DA Lauver EM Driscoll BR Lucchesi, Pharmacology 2008 82 1 67 73 10.1159/000132085 18477858
30. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. L Kupcinskas P Lafolie A Lignell G Kiudelis L Jonaitis K Adamonis LP Andersen T Wadstrom, Phytomedicine 2008 15 67 391 399 10.1016/j.phymed.2008.04.004 18467083
31. Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. V Parisi M Tedeschi G Gallinaro M Varano S Saviano S Piermarocchi, Ophthalmology 2008 115 2 324 333 10.1016/j.ophtha.2007.05.029 17716735
32. Combined conventional/antioxidant "Astaxanthin" treatment for male infertility: a double blind, randomized trial. FH Comhaire Y El Garem A Mahmoud F Eertmans F Schoonjans, Asian J Androl 2005 7 3 257 262 10.1111/j.1745-7262.2005.00047.x 16110353
33. Astaxanthin supplementation does not attenuate muscle injury following eccentric exercise in resistance-trained men. RJ Bloomer A Fry B Schilling L Chiu N Hori L Weiss, Int J Sport Nutr Exerc Metab 2005 15 4 401 412 16286671
34. Effects of astaxanthin supplementation on lipid peroxidation. J Karppi TH Rissanen K Nyyssonen J Kaikkonen AG Olsson S Voutilainen JT Salonen, Int J Vitam Nutr Res 2007 77 1 3 11 10.1024/0300-9831.77.1.3 17685090
35. Gastric inflammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin. LP Andersen S Holck L Kupcinskas G Kiudelis L Jonaitis D Janciauskas H Permin T Wadstrom, FEMS Immunol Med Microbiol 2007 50 2 244 248 10.1111/j.1574-695X.2007.00257.x 17521392
36. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. GA Spiller A Dewell, J Med Food 2003 6 1 51 56 10.1089/109662003765184741 12804020
37. Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients. ML Blackhall RG Fassett JE Sharman DP Geraghty JS Coombes, Nephrol Dial Transplant 2005 20 9 1970 1975 10.1093/ndt/gfh875 15998657
38. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. IB Wilkinson SA Fuchs IM Jansen JC Spratt GD Murray JR Cockcroft DJ Webb, J Hypertens 1998 16 12 Pt 2 2079 2084 10.1097/00004872- 199816121-00033 9886900
39. An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. TA Mori KD Croft IB Puddey LJ Beilin, Anal Biochem 1999 268 1 117 125 10.1006/abio.1998.3037 10036170
40. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. MS Rolph S Zimmer B Bottazzi C Garlanda A Mantovani GK Hansson, Arterioscler Thromb Vasc Biol 2002 22 5 e10 14 10.1161/01.ATV.0000015595.95497. 2F 12006411
41. Ultrasound brachial artery reactivity testing: technical considerations. SE Aeschlimann CK Mitchell CE Korcarz, J Am Soc Echocardiogr 2004 17 6 697 699 10.1016/j.echo.2004.03.017 15163949
42. No relationship between low-density lipoproteins and endothelial function in hemodialysis patients. BS Dalton RG Fassett DP Geraghty R De Ryke JS Coombes, Int J Cardiol 2005 99 2 307 314 10.1016/j.ijcard.2004.02.004 15749192
43. Carotid intima-media thickness testing: technical considerations. CK Mitchell SE Aeschlimann CE Korcarz, J Am Soc Echocardiogr 2004 17 6 690 692 10.1016/j.echo.2004.03.019 15163947
44. non-invasive measurement of surrogate markers of atherosclerosis: carotid intima thickness (c-IMT). TFS Chodakauskas, GE Healthcare 2006
45. Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. T Stompor A Krasniak W Sulowicz A Dembinska-Kiec K Janda K Wojcik B Tabor ME Kowalczyk-Michalek A Zdzienicka E Janusz-Grzybowska, Nephrol Dial Transplant 2005 20 2 404 412 10.1093/ndt/gfh597 15618238
46. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. EM Simmons A Langone MT Sezer JP Vella P Recupero JD Morrow TA Ikizler J Himmelfarb, Transplantation 2005 79 8 914 919 10.1097/01.TP.0000157773.96534.29 15849543
47. Aortic stiffness, living donors, and renal transplantation. SA Bahous A Stephan J Blacher ME Safar, Hypertension 2006 47 2 216 221 10.1161/01.HYP. 0000201234.35551.2e 16401761
48. Living kidney donation: anemia and inflammation in the early postoperative period. DJ Hampel J Pratschke G May P Reinke R Schindler, Transplant Proc 2006 38 3 661 663 10.1016/j.transproceed.2006.01.066 16647436
49. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. J Mercke Odeberg A Lignell A Pettersson P Hoglund, Eur J Pharm Sci 2003 19 4 299 304 10.1016/S0928-0987(03) 00135-0 12885395